Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas.
Antitumor agents
Hematological malignancies
Isoxazoles
Lymphoma
pyrrolo[3′,4’:3,4]cyclohepta[1,2-d][1,2]oxazoles
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
received:
01
02
2023
revised:
10
04
2023
accepted:
11
04
2023
pmc-release:
05
06
2024
medline:
8
5
2023
pubmed:
18
4
2023
entrez:
17
4
2023
Statut:
ppublish
Résumé
Unsatisfactory outcomes for relapsed/refractory lymphoma patients prompt continuing efforts to develop new therapeutic strategies. Our previous studies on pyrrole-based anti-lymphoma agents led us to synthesize a new series of twenty-six pyrrolo[3',4':3,4]cyclohepta[1,2-d] [1,2]oxazole derivatives and study their antiproliferative effects against a panel of four non-Hodgkin lymphoma cell lines. Several candidates showed significant anti-proliferative effects, with IC
Identifiants
pubmed: 37068384
pii: S0223-5234(23)00338-0
doi: 10.1016/j.ejmech.2023.115372
pmc: PMC10287037
mid: NIHMS1893052
pii:
doi:
Substances chimiques
Tubulin
0
Antineoplastic Agents
0
Oxazoles
0
Tubulin Modulators
0
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115372Subventions
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Francesco Bertoni reports financial support was provided by ADC Therapeutics, Bayer AG, Cellestia, Helsinn, HTG Molecular Diagnostics, ImmunoGen, Menarini Ricerche, NEOMED Therapeutics 1, Nordic Nanovector ASA, Helsinn, Menarini. Eugenio Gaudio reports a relationship with Helsinn Healthcare SA that includes: employment.
Références
Pharmacol Ther. 2020 Jul;211:107552
pubmed: 32305312
Bioorg Chem. 2019 Mar;83:511-519
pubmed: 30458413
Eur J Med Chem. 2016 Nov 29;124:840-851
pubmed: 27643641
J Biol Chem. 1999 Sep 3;274(36):25543-9
pubmed: 10464286
Eur J Med Chem. 2021 Feb 15;212:113122
pubmed: 33401199
Int J Mol Sci. 2022 Sep 06;23(18):
pubmed: 36142133
J Med Chem. 2020 Oct 22;63(20):12023-12042
pubmed: 32986419
J Mol Biol. 2014 Apr 17;426(8):1848-60
pubmed: 24530796
J Med Chem. 2022 Oct 13;65(19):12781-12801
pubmed: 36191148
J Med Chem. 2015 Apr 9;58(7):3209-22
pubmed: 25785605
Eur J Med Chem. 2016 May 23;114:220-31
pubmed: 26994690
J Biol Chem. 2010 Oct 8;285(41):31672-81
pubmed: 20675373
J Chem Biol. 2017 Apr 4;10(3):91-104
pubmed: 28684996
Nature. 2005 May 26;435(7041):519-22
pubmed: 15917812
J Med Chem. 2016 Aug 11;59(15):7223-38
pubmed: 27428868
J Med Chem. 2022 Sep 22;65(18):12095-12123
pubmed: 36068975
Endocr Relat Cancer. 2008 Jun;15(2):499-510
pubmed: 18509002
Eur J Med Chem. 2022 Dec 5;243:114744
pubmed: 36242921
Eur J Med Chem. 2022 May 5;235:114292
pubmed: 35339838
Eur J Med Chem. 2020 Oct 15;204:112631
pubmed: 32898816
Mar Drugs. 2020 Dec 04;18(12):
pubmed: 33291602
Molecules. 2021 Feb 26;26(5):
pubmed: 33652850
Biochem Pharmacol. 2008 Feb 15;75(4):810-25
pubmed: 18022602
Cell Death Differ. 2003 Jun;10(6):709-17
pubmed: 12761579
BMC Bioinformatics. 2009 Dec 03;10 Suppl 15:S10
pubmed: 19958509
ChemMedChem. 2016 Aug 19;11(16):1721-33
pubmed: 27008476
Arch Pharm Res. 2022 Nov;45(11):806-821
pubmed: 36399284
Eur J Med Chem. 2022 Jul 5;237:114399
pubmed: 35468516
Drug Dev Res. 2022 Sep;83(6):1331-1341
pubmed: 35749723
Eur J Med Chem. 2014 Mar 3;74:340-57
pubmed: 24486413